Allergan
Founded in 1948, Allergen became a public company in 1970 and merged with SmithKline Beecham in 1980. It became independent again in 1989. Allergen’s research interests today include: glaucoma, retinal disease, dry eye, pain, movement disorders, retinoid technology, psoriasis, acne, photo-damage, metabolic disease and cancer.[1]
In 2006, Allergen was ranked 37th in the Top 50 pharmaceutical companies worldwide, with 2005 Global Sales of $2.32 and a Research and Design spend of $387M. [2]. Allergan operates in over 100 countries and has approximately 7,000 employees worldwide. Allergen markets several leading pharmaceutical products including BOTOX.
Allergen Holdings Limited and Allergan Limited are UK subsidiaries of Allergen, Inc.[3]
The Allergen Foundation is an offshoot of Allergen Inc. Since 1998 the Allergen Foundation has given grants of approximately $12M to the arts, civic programs, education and health and human services.
References
- ↑ http://www.allergan.co.uk/careers/culture.htm (Allergen Careers Information)
- ↑ Gray, N. (2006) Changing Landscapes: A special Report on the World’s Top 50 Pharma Companies, Pharmaceutical Executive. Available online at: pharmexec.findpharma.com/pharmexec/2005-Pharm-Exec-50-revised/ArticleStandard/Article/detail/354138
- ↑ http://sec.edgar-online.com/2004/03/05/0000892569-04-000307/Section36.asp (EDGARonline)
